{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-001316","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.957511+00:00","generated_at":"2026-05-30T03:20:04.647034+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunic Q3 net loss $24.4M; positive ENSURE futility analysis; cash runway into Q3 2025","bullets":["Net loss Q3 2024: $24.4M ($0.24/share) vs $22.8M ($0.51/share) in Q3 2023.","Cash $59.1M as of Sep 30, 2024; expected to fund operations into Q3 2025.","Phase 3 ENSURE futility analysis positive: IDMC recommends continuation without sample size increase.","Top-line data from Phase 2 CALLIPER (PMS) expected April 2025; ENSURE-1 completion Q2 2026.","New leadership: Jason Tardio appointed COO/President; Werner Gladdines promoted to CDO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-001316","json":"https://secwatch.observer/filing/0001193805-24-001316.json","markdown":"https://secwatch.observer/filing/0001193805-24-001316.md","text":"https://secwatch.observer/filing/0001193805-24-001316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001316/0001193805-24-001316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001316/e663991_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:20:04.647034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}